Corcept Therapeutics (CORT)

The company’s marketed product is Korlym, a mifepristone tablet approved in the United States for the treatment of hyperglycemia secondary to hypercortisolism in certain adults with endogenous Cushing’s syndrome who have type 2 diabetes or glucose intolerance and are not candidates for surgery or have not responded to surgery. Corcept also markets an authorized generic version of the product. This commercial base supports the company’s broader research and development strategy.

Corcept’s pipeline includes several proprietary cortisol modulators designed to improve selectivity and expand the therapeutic reach of the platform. Relacorilant is one of its most advanced candidates and is being evaluated for conditions including Cushing’s syndrome and certain solid tumors. Other candidates, including dazucorilant and miricorilant, are being studied across areas such as oncology, neuromuscular disease, metabolic dysfunction-associated steatohepatitis, and other serious disorders.

The company is distinctive because it applies a single biological mechanism across multiple disease categories rather than operating as a broad, diversified drug developer. Its value depends on continued Korlym sales, clinical trial outcomes, regulatory progress, intellectual property protection, and its ability to demonstrate that newer cortisol modulators can offer meaningful benefits in difficult-to-treat diseases.